Ziconotide for Nerve Damage
Research, mechanism, dosing, and effectiveness of Ziconotide for nerve damage.
Quick Answer
Ziconotide is FDA-approved for severe chronic pain unresponsive to other treatments.
Evidence Level
FDA Approved
Typical Dose
Intrathecal administration only
Results Timeline
Pain relief within days
FDA Status
FDA Approved
How Ziconotide Works for Nerve Damage
Blocks N-type calcium channels in spinal cord to interrupt pain signals.
About Nerve Damage
Support for nerve repair and regeneration.
Research Evidence
Effective for severe chronic pain refractory to other treatments. Studies show significant pain reduction without tolerance development. Complex delivery limits use to specialized pain centers.
Dosing for Nerve Damage
Recommended Dose
Intrathecal administration only
Frequency
See research protocols
Administration
Intrathecal infusion only
Duration
Chronic use via intrathecal pump
Note: Limited anecdotal data. Refer to research dosing section.
What to Expect
Initial adjustment period. Some users may notice subtle changes.
Early benefits often become noticeable. Continue consistent use.
Most users report meaningful improvements by this point.
Full effects typically realized. Reassess and adjust as needed.
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Dizziness (40%)
- •Nausea
- •Confusion
- •Hallucinations
- •Depression
- •Suicidal ideation
Frequently Asked Questions
Does Ziconotide help with nerve damage?
Ziconotide is FDA-approved for severe chronic pain unresponsive to other treatments.
How does Ziconotide work for nerve damage?
Blocks N-type calcium channels in spinal cord to interrupt pain signals....
What dose of Ziconotide should I use for nerve damage?
Intrathecal administration only
How long until I see results?
Pain relief within days
Other Peptides for Nerve Damage
These peptides are also researched for nerve damage.
BPC-157
PreclinicalA synthetic peptide derived from a protein found in human gastric juice. Known for its remarkable tissue healing properties across multiple body systems. FDA classified as Category 2 in 2023, restricting compounding.
TB-500
PreclinicalA synthetic 17-amino acid fragment of Thymosin Beta-4 (TB-4). Unlike TB-4, TB-500 has a longer half-life (~2-4 days vs ~2 hours) and is the active region responsible for tissue repair and cell migration. Note: Many vendors mislabel TB-4 as 'TB-500' in premixed products.
Pentadecapeptide
PreclinicalThe full 15-amino acid sequence that includes BPC-157. While BPC-157 is more commonly discussed, the full pentadecapeptide has similar healing properties derived from gastric juice.
Thymosin Beta-4
Clinical TrialsThe full 43-amino acid protein that TB-500 is derived from. Naturally occurring in most human tissues, TB-4 has a shorter half-life (~2 hours) compared to its synthetic fragment TB-500 (~2-4 days). Often mislabeled as 'TB-500' by vendors in premixed products.
Educational Information Only
This information about Ziconotide for nerve damage is for educational purposes only. Always consult with qualified healthcare providers before using any peptide. Individual results may vary.